# Efficacy and Safety of Ginkgo Biloba in Middle-aged Cognitively Intact Adults

> **NCT02181972** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 120 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Gingko biloba
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02181972
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-05
- **Primary completion:** 2002-11
- **Final completion:** —
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2014-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02181972

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02181972, "Efficacy and Safety of Ginkgo Biloba in Middle-aged Cognitively Intact Adults". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02181972. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*